ARTA
ACAD icon

A.R.T. Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

A.R.T. Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50,130
Closed -$2.15M – 38
2019
Q4 		$2.15M Buy
50,130
+28,700
+134% +$1.25M 0.11% 273
2019
Q3 		$771K Sell
21,430
-100
-0.5% -$3.03K 0.04% 671
2019
Q2 		$575K Sell
21,530
-30,100
-58% -$769K 0.03% 693
2019
Q1 		$1.39M Buy
+51,630
New +$1.21M 0.08% 360
2018
Q3 		– Sell
-91,230
Closed -$1.39M – 1365
2018
Q2 		$1.39M Buy
+91,230
New +$1.63M 0.06% 490
2018
Q1 		– Sell
-59,605
Closed -$1.79M – 1463
2017
Q4 		$1.79M Buy
+59,605
New +$1.91M 0.08% 406
2017
Q1 		– Sell
-12,100
Closed -$348K – 1391
2016
Q4 		$348K Buy
+12,100
New +$320K 0.02% 888
2016
Q2 		– Sell
-155,645
Closed -$4.35M – 1317
2016
Q1 		$4.35M Buy
155,645
+148,208
+1,993% +$3.23M 0.19% 125
2015
Q4 		$265K Sell
7,437
-86,032
-92% -$3.03M 0.01% 1099
2015
Q3 		$3.09M Buy
+93,469
New +$3.89M 0.11% 245
2015
Q1 		– Sell
-11,788
Closed -$374K – 1392
2014
Q4 		$374K Buy
+11,788
New +$334K 0.01% 1022

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

A.R.T. Advisors's ACAD Position: Q1 2020 in Review

A.R.T. Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 50,130 shares — an estimated $2.15M sold.

A.R.T. Advisors first reported a position in ACAD in Q4 2014 and held it in 11 quarters. The position peaked at $4.35M in Q1 2016. 245 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

  • A.R.T. Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 50,130 Acadia Pharmaceuticals shares in Q1 2020, an estimated $2.15M.
  • A.R.T. Advisors first reported a position in Acadia Pharmaceuticals in Q4 2014 and held it in 11 quarters.
  • A.R.T. Advisors's Acadia Pharmaceuticals position peaked at $4.35M in Q1 2016.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.